BMS
NICE completes Forxiga U-turn
June 26, 2013Sales and Marketing BMS, Forxiga, NICE
Bristol-Myers Squibb and AstraZeneca are celebrating after NICE reversed its decision from earlier this year and is now recommending their …
Lilly diabetes drug beats rivals
June 25, 2013Sales and Marketing BMS, diabetes, dulaglutide, lilly
New clinical trial results have shown Lilly’s investigational type 2 diabetes drug has beaten its three nearest rivals in reducing …
BMS appoints Harman International chief executive
June 24, 2013Manufacturing and Production, Research and Development, Sales and Marketing BMS
Bristol-Myers Squibb has appointed Harman’s chief executive Dinesh Paliwal to its Board of directors.Paliwal will serve as a member of …
NICE thumbs-up for Abilify
June 7, 2013Sales and Marketing Abilify, BMS, NICE, Otsuka
Adolescents who suffer from bipolar disorder should be treated on the NHS with Otsuka Pharmaceuticals’ Abilify, according to draft guidance …
AstraZeneca/BMS drug granted speedy FDA review
June 5, 2013Sales and Marketing AstraZeneca, BMS, lipodystrophy
AstraZeneca and partner Bristol-Myers Squibb have been granted a priority review for their rare disease drug metreleptin. The medicine is …
HCV agreement for Merck and BMS
April 23, 2013Research and Development, Sales and Marketing BMS, HCV, Merck
Merck & Co and Bristol-Myers Squibb have signed a non-exclusive agreement to conduct a Phase II trial looking at a …
Bristol-Myers Squibb appoints executive as another retires
April 10, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS
Bristol-Myers Squibb has announced the appointment of Francis Cuss as executive VP and chief scientific officer following Elliott Sigal’s intentions …
Merck KGaA/BMS China deal
March 22, 2013Sales and Marketing BMS, Merck KGaA, diabetes
Merck KGaA and Bristol-Myers Squibb are to co-promote the German firm’s veteran diabetes drug Glucophage in different formations in China. …
Eliquis approved by NICE
February 28, 2013Sales and Marketing BMS, Eliquis, NICE, Pfizer
In a move which will cheer Bristol-Myers Squibb and Pfizer, NICE has recommended oral blood-thinner Eliquis for use on the …
BMS hires Ann Powell Judge from Shire
February 14, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ann Powell Judge, BMS, Shire
BMS has announced that Ann Powell Judge will join the company as senior vice president, Human Resources.From March Judge will …
BMS in $438m OTC deal
February 14, 2013Sales and Marketing BMS, Reckitt Benckiser
Bristol-Myers Squibb has signed over the rights to sell, distribute and market half a dozen of its medicines, mainly sold …
NICE rejects Forxiga
February 1, 2013Sales and Marketing AstraZeneca, BMS, Forxiga, NICE, diabetes
NICE has given the thumbs-down to AstraZeneca and Bristol-Myers Squibb’s first-in-class type II diabetes treatment Forxiga. The drug was approved …
Roche’s Burgess to head up discovery at BMS
January 18, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Burgess
Bristol-Myers Squibb has appointed Mike Burgess as senior vice president, Discovery Medicine and Clinical Pharmacology. He will report to Francis …
Eliquis in UK for AF
December 13, 2012Sales and Marketing AF, BMS, Eliquis, NVAF, Pfizer
Eliquis has been made available in the UK today to prevent stroke and systemic embolism in patients with nonvalvular atrial …
Further indications for Eliquis
November 22, 2012Sales and Marketing BMS, Eliquis, NVAF, Pfizer, Pradaxa, Xarelto
Bristol-Myers Squibb and Pfizer’s oral blood-thinner Eliquis has been approved in Europe to prevent stroke in patients with nonvalvular atrial …
